Tirzepatide
SURMOUNT-1
Eli Lilly · Phase 3 · Recruiting · Enrollment 2539
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Arm 1: Tirzepatide 5 mg once weekly + lifestyle intervention | n/r | n/r | n/r | n/r |
| Arm 2: Tirzepatide 10 mg once weekly + lifestyle intervention | n/r | n/r | n/r | n/r |
| Arm 3: Tirzepatide 15 mg once weekly + lifestyle intervention | n/r | n/r | n/r | n/r |
| Arm 4: Placebo once weekly + lifestyle intervention | n/r | n/r | n/r | n/r |
Not shown
- Arm 1: Tirzepatide 5 mg once weekly + lifestyle intervention: endpoint not reported
- Arm 2: Tirzepatide 10 mg once weekly + lifestyle intervention: endpoint not reported
- Arm 3: Tirzepatide 15 mg once weekly + lifestyle intervention: endpoint not reported
- Arm 4: Placebo once weekly + lifestyle intervention: endpoint not reported